100,000 Shares in Urogen Pharma $URGN Bought by Elmind Capital LP

Elmind Capital LP bought a new position in shares of Urogen Pharma (NASDAQ:URGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $2,342,000. Urogen Pharma comprises about 0.7% of Elmind Capital LP’s holdings, making the stock its 26th largest position.

A number of other hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the period. Main Street Financial Solutions LLC lifted its holdings in Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after acquiring an additional 1,968 shares during the period. Barclays PLC lifted its holdings in Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after acquiring an additional 2,125 shares during the period. Finally, Osaic Holdings Inc. lifted its holdings in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares during the period. Institutional investors own 91.29% of the company’s stock.

Analyst Ratings Changes

URGN has been the topic of a number of recent analyst reports. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a report on Wednesday, June 3rd. LADENBURG THALM/SH SH assumed coverage on Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Finally, D. Boral Capital restated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Urogen Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Urogen Pharma Price Performance

Shares of URGN opened at $32.81 on Thursday. The firm has a market cap of $1.60 billion, a PE ratio of -11.93 and a beta of 1.59. The stock’s fifty day moving average price is $26.51 and its two-hundred day moving average price is $22.90. Urogen Pharma has a 1 year low of $12.73 and a 1 year high of $33.40.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. Sell-side analysts anticipate that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Insider Activity

In other Urogen Pharma news, insider Mark Schoenberg sold 5,222 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $27.30, for a total value of $142,560.60. Following the sale, the insider directly owned 139,763 shares in the company, valued at $3,815,529.90. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.80% of the stock is currently owned by insiders.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.